You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

81 search results for: coexisting diseases

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct <b>Diseases</b> with Shared Characteristics

interactivity

Atopic Dermatitis (AD) and Prurigo Nodularis (PN): Distinct Diseases with Shared Characteristics

5 min

Dermatology

Explore our interactive tool showcasing the unique and shared features, burden, and risk factors of atopic dermatitis and prurigo nodularis.

expert video

Cumulative Exposure to Corticosteroids in Type 2 Inflammatory Diseases

1 min

Type 2 Inflammation

Dr. Evan Dellon highlights potential risks with cumulative use of steroids for treatment of various coexisting type 2 inflammatory diseases.

Infographic

Skin Barrier Dysfunction and Increased Risk of Allergen Sensitization May Impact Atopic March in Atopic Dermatitis (AD)

5 min

Dermatology

An infographic exploring the process of allergen sensitization and the impact it may have on the development of atopic comorbidities in children with AD.

Infographic

(DRAFT) The Role of Type 2 Inflammation in Multiple Disease Trajectories

5 min

Dermatology

An infographic exploring the shared and distinct clinical characteristics of atopic dermatitis and prurigo nodularis.

expert video

PN and AD: Distinct Diseases with Underlying Type 2 Inflammation

1 min

Dermatology

Prurigo nodularis (PN) and atopic dermatitis (AD): Distinct diseases with underlying type 2 inflammation – highlights from the ADVENT symposium at AAD 2023.

interactivity

The Role of Type 2 Inflammation in Multiple Disease Trajectories

5 min

Type 2 Inflammation

How type 2 inflammation drives atopic dermatitis and underlies other atopic diseases across multiple disease trajectories including the atopic march.

expert video

AD and PN: Diagnosis and Impact on Quality of Life

1 min

Dermatology

Approaches to diagnosis and the multidimensional burden of atopic dermatitis and prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023.

expert video

Cutaneous Manifestations in AD & PN: Role of Type 2 Inflammation video

24 min

Dermatology

Type 2 inflammation in the distinct cutaneous manifestations of atopic dermatitis and prurigo nodularis – a clip from the ADVENT symposium at AAD 2023.

expert video

Fibrosis and Type 2 Inflammation in PN

2 min

Dermatology

The pathophysiology of fibrosis, a key component of skin manifestations in prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023

expert video

Neuroimmune Axis and Pruritus in PN

2 min

Dermatology

Changes in nerve density and dysfunction of the neuroimmune axis drive pruritus in prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023.

expert video

Presentation and Diagnosis of AD and PN

15 min

Dermatology

Presentation of atopic dermatitis and prurigo nodularis, and the impact of PN as an intensely pruritic disease – Clip from the ADVENT symposium at AAD 2023.

expert video

Type 2 Inflammation and Cutaneous Manifestation in AD and PN

5 min

Dermatology

Pathophysiology of type 2 inflammation in the skin in two distinct, chronic pruritic dermatoses – atopic dermatitis and prurigo nodularis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: ArgentinaChange country/region